Tag Archives: Amgen

Novartis Wins Landmark Biosimilar Approval

Posted on March 9, 2015 by Warren Woessner

Novartis Navigates The FDA-ACA Maze – Gets Approval For Generic Neuprogen. Amgen will soon find itself in a price war with Sandoz – a Novartis company – as it tries to maintain its share of the market for Neuprogen (filgraslim). … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged Amgen, biotechnology, Federal Circuit, intellectual property, ip, Neuprogen, Novartis, Sandoz, Warren Woessner | Leave a comment

Patents4Life is Six Years Old this Month. Happy Birthday to Us!

Posted on March 3, 2015 by Warren Woessner

Six years ago, In re Kubin caused a flurry of concern among biotech practitioners, and a short article on this decision was the first post on Patents4Life. That was a pretty big “story” at the time but we all had … Continue reading →

Posted in Miscellaneous | Tagged Amgen, biotechnology, FDA, Kimble v. Marvell, Nautilus, Patent Law, s. 101, Teva v. Sandoz, Tharasense, USPTO | 4 Comments

FDA Accepts First Biosimilar Application for Review

Posted on July 28, 2014 by Warren Woessner

In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading →